Hero Image
Assets / Buttons / UI / Play Button / Large clear hover Assets / Buttons / UI / Play Button / Large clear hover

Research

We run to, not from, the world’s biggest health challenges.

The journey to discovery is guided by science – and inspired by patients

We use the power of leading-edge science to save and improve lives around the world. The path to discovery is often unclear, but we are tireless in seeking solutions for some of the world’s most difficult health challenges.

Our work in numbers

~21.8K

people employed in research and development

$30.5B

invested in R&D in 2023

We address the world’s most difficult health challenges, following leading-edge science

Hero_RGB_Discovery-Blue
Discovery & development

Step inside Merck Research Laboratories (MRL) where our quest to save and improve lives through research and development begins

Pipeline_Image
Pipeline

We’re focused on inventing new medicines and vaccines to help more people

B5 we work to deliver
Products

Our focus on breakthrough science is working

Clinical trials

Our progress is due in large part to the important and tough scientific questions we set out to answer with our trials and collaborations. We are grateful to the thousands of volunteers who participate in our clinical trials — making this all possible.

Father playing with young son at breakfast table

Our commitment to patients is unwavering

As long as there are still patients in hospitals, doctors and nurses desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here, fighting with all we have to deliver more, sooner.

Discovery starts here

Our scientists are applying the latest groundbreaking research technologies and revolutionizing how we discover and develop medicines and vaccines

View our stories

Taking on Zaire ebolavirus

How science and innovation fuel our efforts to help combat a rare but potentially deadly disease

Read more

Next: Taking on Zaire ebolavirus

Teaming up with Eisai to help fight cancer

How we're leveraging each other’s unique strengths to help advance cancer research

Read more

Next: Teaming up with Eisai to help fight cancer

How Merck scientists are driving next-generation cancer research

Our scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit cancer growth

Read more

Next: How Merck scientists are driving next-generation cancer research

In our commitment to R&D, the numbers speak for themselves

We follow the science where we can make the greatest difference

Read more

Next: In our commitment to R&D, the numbers speak for themselves

Our Q4 and full-year 2023 earnings report

Merck’s (NYSE: MRK) Q4 and full-year 2023 results reflect sustained growth across oncology and vaccines. Our company announced Q4 worldwide sales of $14.6 billion, an increase of 6% from Q4 2022. Full-year 2023 worldwide sales were $60.1 billion, an increase of 1% from full-year 2022. ​ “2023 was another very strong year for Merck. I am extremely pleased […]

Read more

Next: Our Q4 and full-year 2023 earnings report

Taking on Zaire ebolavirus

How science and innovation fuel our efforts to help combat a rare but potentially deadly disease

Read more

Next: Taking on Zaire ebolavirus

Teaming up with Eisai to help fight cancer

How we're leveraging each other’s unique strengths to help advance cancer research

Read more

Next: Teaming up with Eisai to help fight cancer

How Merck scientists are driving next-generation cancer research

Our scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit cancer growth

Read more

Next: How Merck scientists are driving next-generation cancer research

In our commitment to R&D, the numbers speak for themselves

We follow the science where we can make the greatest difference

Read more

Next: In our commitment to R&D, the numbers speak for themselves

Our Q4 and full-year 2023 earnings report

Merck’s (NYSE: MRK) Q4 and full-year 2023 results reflect sustained growth across oncology and vaccines. Our company announced Q4 worldwide sales of $14.6 billion, an increase of 6% from Q4 2022. Full-year 2023 worldwide sales were $60.1 billion, an increase of 1% from full-year 2022. ​ “2023 was another very strong year for Merck. I am extremely pleased […]

Read more

Next: Our Q4 and full-year 2023 earnings report

Previous
Next
a cow with a blue sky background

Protecting animal health

Our Animal Health business is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them.